[go: up one dir, main page]

TNSN99218A1 - Nouveaux composes azabicycliques a substitution heteroaryl- ethyl/benzisoxazole, leur procede de production et composition pharmaceutique les contenant. - Google Patents

Nouveaux composes azabicycliques a substitution heteroaryl- ethyl/benzisoxazole, leur procede de production et composition pharmaceutique les contenant.

Info

Publication number
TNSN99218A1
TNSN99218A1 TNTNSN99218A TNSN99218A TNSN99218A1 TN SN99218 A1 TNSN99218 A1 TN SN99218A1 TN TNSN99218 A TNTNSN99218 A TN TNSN99218A TN SN99218 A TNSN99218 A TN SN99218A TN SN99218 A1 TNSN99218 A1 TN SN99218A1
Authority
TN
Tunisia
Prior art keywords
same
producing
heteroaryl
ethyl
pharmaceutical composition
Prior art date
Application number
TNTNSN99218A
Other languages
English (en)
Inventor
Michael Bright Gene
Amratlal Desai Kishor
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN99218A1 publication Critical patent/TNSN99218A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'INVENTION CONCERNE DES COMPOSES DE FORMULE I : DANS LAQUELE R1, R2, R3, ET R4 SONT CHOISIS INDEPENDAMMENT ENTRE L'HYDROGENE, ET DES RADICAUX ALKYLE EVENTUELLEMENT FLUORES, ET X REPRESENTE CH OU N, OU LEURS SELS ACCEPTABLES DU POINT DE VUE PHARMACEUTIQUE. ELLE CONCERNE AUSSI UN PROCEDE DE PRODUCTION DE CES COMPOSES. LES COMPOSES DE L'INVENTION SONT UTILES COMME AGENTS PSYCHOTROPES.
TNTNSN99218A 1998-12-28 1999-11-17 Nouveaux composes azabicycliques a substitution heteroaryl- ethyl/benzisoxazole, leur procede de production et composition pharmaceutique les contenant. TNSN99218A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11395798P 1998-12-28 1998-12-28

Publications (1)

Publication Number Publication Date
TNSN99218A1 true TNSN99218A1 (fr) 2005-11-10

Family

ID=22352526

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN99218A TNSN99218A1 (fr) 1998-12-28 1999-11-17 Nouveaux composes azabicycliques a substitution heteroaryl- ethyl/benzisoxazole, leur procede de production et composition pharmaceutique les contenant.

Country Status (43)

Country Link
US (1) US6525196B1 (fr)
EP (1) EP1140931B1 (fr)
JP (1) JP2002533463A (fr)
KR (1) KR100417506B1 (fr)
CN (1) CN1332740A (fr)
AP (1) AP2001002188A0 (fr)
AR (1) AR024840A1 (fr)
AT (1) ATE260278T1 (fr)
AU (1) AU761711B2 (fr)
BG (1) BG105710A (fr)
BR (1) BR9916807A (fr)
CA (1) CA2356985C (fr)
CO (1) CO5150179A1 (fr)
CR (1) CR6398A (fr)
CZ (1) CZ291163B6 (fr)
DE (1) DE69915113T2 (fr)
DK (1) DK1140931T3 (fr)
DZ (1) DZ2933A1 (fr)
EA (1) EA003099B1 (fr)
EE (1) EE04439B1 (fr)
ES (1) ES2214892T3 (fr)
GE (1) GEP20043227B (fr)
GT (1) GT199900224A (fr)
HR (1) HRP20010488A2 (fr)
HU (1) HUP0104852A3 (fr)
ID (1) ID30117A (fr)
IL (1) IL143385A0 (fr)
IS (1) IS5951A (fr)
MA (1) MA26706A1 (fr)
NO (1) NO20013215L (fr)
NZ (1) NZ511964A (fr)
OA (1) OA11742A (fr)
PA (1) PA8486701A1 (fr)
PE (1) PE20001234A1 (fr)
PT (1) PT1140931E (fr)
SK (1) SK9002001A3 (fr)
TN (1) TNSN99218A1 (fr)
TR (1) TR200101979T2 (fr)
TW (1) TW523514B (fr)
UA (1) UA62015C2 (fr)
WO (1) WO2000039128A1 (fr)
YU (1) YU44301A (fr)
ZA (1) ZA200105041B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855729B2 (en) * 2001-02-20 2005-02-15 Timothy G. Dinan Treatment of fibromyalgia and related fatigue syndromes using antagonists or partial agonists of 5HT1a receptors
GB0203778D0 (en) * 2002-02-18 2002-04-03 Glaxo Group Ltd Compounds
AU2004220327B2 (en) * 2003-03-12 2010-06-24 Pfizer Products Inc. Pyridyloxymethyl and benzisoxazole azabicyclic derivatives
GB0316915D0 (en) * 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
BRPI0507250A (pt) * 2004-01-29 2007-06-26 Pfizer Prod Inc combinações para tratar desordens do snc
AR049478A1 (es) 2004-03-25 2006-08-09 Solvay Pharm Bv Un procedimiento para la preparacion de 3-amino-8-(1-piperazinil)-2h-1-benzopiran-2-ona. sales e hidratos y composiciones farmaceuticas.
AR048112A1 (es) * 2004-03-25 2006-03-29 Solvay Pharm Bv Derivados de 1-(2h-1-benzopiran-2-on-8-il)-piperazina para el tratamiento de dolor
MX2007002842A (es) * 2004-09-10 2007-04-30 Pfizer Prod Inc Metodos de tratamiento de trastornos cognitivos que usan derivados azabiciclicos de piridiloximetilo y benzoisoxazol.
WO2006027691A2 (fr) * 2004-09-10 2006-03-16 Pfizer Products Inc. Methodes de traitement des troubles de l'humeur au moyen de derives azabicycliques de pyridyloxymethyle et de benzisoxazole
DE102005026194A1 (de) * 2005-06-06 2006-12-07 Grünenthal GmbH Substituierte N-Benzo[d]isoxazol-3-yl-amin-Derivate und deren Verwendung zur Herstellung von Arzneimitteln
WO2008019431A1 (fr) * 2006-08-14 2008-02-21 Brc Operations Pty Limited Procédé et compositions pour réguler simultanément la mémoire et l'humeur
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2020183011A1 (fr) 2019-03-14 2020-09-17 Institut Curie Inhibiteurs de htr1d et leurs utilisations dans le traitement du cancer
AU2020407614A1 (en) * 2019-12-20 2022-08-18 The Jackson Laboratory Molecular targets for addiction

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5157034A (en) * 1991-02-27 1992-10-20 Pfizer Inc. Neuroleptic perhydro-1H-pyrido[1,2-a]pyrazines
GB9410512D0 (en) * 1994-05-25 1994-07-13 Smithkline Beecham Plc Novel treatment
EP0763034A1 (fr) * 1994-05-28 1997-03-19 Smithkline Beecham Plc Derives amide a activite antagoniste par rapport a 5ht1d
TR199902590T2 (xx) * 1997-04-18 2000-06-21 Smithkline Beecham P.L.C. Birle�ik 5HT1A 5HT1B ve 5HT1D resept�r antagonist aktivitesi olan indol t�revleri.
IT1293807B1 (it) * 1997-08-01 1999-03-10 Recordati Chem Pharm Derivati 1- (n-fenilaminoalchil) piperazinici sostituiti alla posizione 2 dell'anello fenilico
PA8469101A1 (es) * 1998-04-09 2000-09-29 Pfizer Prod Inc Ligandos azabiciclicos de receptores 5ht1

Also Published As

Publication number Publication date
PE20001234A1 (es) 2000-11-07
EP1140931B1 (fr) 2004-02-25
GEP20043227B (en) 2004-04-26
CA2356985A1 (fr) 2000-07-06
CR6398A (es) 2004-03-24
DE69915113D1 (de) 2004-04-01
ID30117A (id) 2001-11-08
NO20013215D0 (no) 2001-06-27
HUP0104852A2 (hu) 2002-05-29
HRP20010488A2 (en) 2002-08-31
HUP0104852A3 (en) 2002-12-28
NZ511964A (en) 2003-08-29
CN1332740A (zh) 2002-01-23
CO5150179A1 (es) 2002-04-29
AR024840A1 (es) 2002-10-30
YU44301A (sh) 2004-07-15
SK9002001A3 (en) 2002-04-04
KR20010092455A (ko) 2001-10-25
EP1140931A1 (fr) 2001-10-10
AU761711B2 (en) 2003-06-05
IS5951A (is) 2001-05-22
GT199900224A (es) 2001-06-15
EA200100517A1 (ru) 2001-12-24
WO2000039128A1 (fr) 2000-07-06
KR100417506B1 (ko) 2004-02-05
CZ291163B6 (cs) 2003-01-15
DE69915113T2 (de) 2004-08-26
CA2356985C (fr) 2006-08-08
OA11742A (en) 2005-05-13
ES2214892T3 (es) 2004-09-16
EE200100346A (et) 2002-12-16
NO20013215L (no) 2001-08-27
BR9916807A (pt) 2001-10-23
EA003099B1 (ru) 2002-12-26
TW523514B (en) 2003-03-11
DZ2933A1 (fr) 2004-03-15
DK1140931T3 (da) 2004-04-19
PA8486701A1 (es) 2000-09-29
IL143385A0 (en) 2002-04-21
PT1140931E (pt) 2004-05-31
BG105710A (en) 2002-02-28
JP2002533463A (ja) 2002-10-08
CZ20012386A3 (cs) 2002-02-13
AP2001002188A0 (en) 2001-06-30
UA62015C2 (en) 2003-12-15
MA26706A1 (fr) 2004-12-20
TR200101979T2 (tr) 2001-12-21
ATE260278T1 (de) 2004-03-15
AU6361499A (en) 2000-07-31
US6525196B1 (en) 2003-02-25
EE04439B1 (et) 2005-02-15
ZA200105041B (en) 2002-06-20

Similar Documents

Publication Publication Date Title
TNSN99218A1 (fr) Nouveaux composes azabicycliques a substitution heteroaryl- ethyl/benzisoxazole, leur procede de production et composition pharmaceutique les contenant.
TNSN97110A1 (fr) Derives de 2-(2-oxo-ethylidene)-imidazolidine-4-one, procede pour leur preparation et compositions pharmaceutiques les contenant
CA2014518A1 (fr) Lipopolyamines, leur preparation et leur emploi
MA24694A1 (fr) Derives de thienopyrimidine et thienopyridine utiles comme agents anticancereux, et compositions les contenant.
TNSN98053A1 (fr) Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions les contenant.
HUP9802814A2 (hu) Szelektív béta3 adrenergiás agonista hatású vegyületek, e vegyületeket tartalmazó gyógyászati készítmények, eljárás előállításukra és alkalmazásuk
LU90317I2 (fr) Tacrolimus et ses sels et dérivés pharmaceutiquement acceptables
DE60127595D1 (de) Inhibitoren der TNF-Alpha Bildung zur Behandlung von Autoimmunerkrankungen
TNSN97127A1 (fr) Derives de benzylamine amido-substitues, leurs derives precurseurs de medicaments, leur procede de preparation, compositions pharmaceutiques les contenant et methode de traitement les utilisant
TW375615B (en) Galanthamine derivatives and their use as medicaments
ATE211474T1 (de) Galanthamin derivate, verfahren zu ihrer herstellung und ihre verwendung als medikamente
FR2440946A2 (fr) Nouveaux benzamides heterocycliques substitues, leurs procedes de preparation et leur application comme modificateurs du comportement
ATE19773T1 (de) Nitroaliphatische verbindungen, verfahren zu deren herstellung und deren verwendung.
JPS57106695A (en) Anthracycline g lycoside compound
FR2803593B1 (fr) Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant
EP0658585A3 (fr) Dérivés d'aminophénylalanine, procédé pour leur, production leur usage et agents contenant ceux-ci comme anticoagulants.
MA28286A1 (fr) Dérivés de 1-N-phenyl-amino-1H-imidazole et compositions pharmaceutiques les contenant
CA2364199A1 (fr) Nouveaux derives bicycliques d'amino-pyrazinones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2440353A1 (fr) Nouveaux arylethanols, leurs procedes d'obtention et leur emploi comme medicament
HU0004701D0 (fr)
JO2289B1 (en) Exporters of NMDA compounds for the future
SE9802546D0 (sv) Medicinal product and method for treatment and prevention of dyskinesia
FR2795727B1 (fr) Nouveaux derives benzodioxanne imidazolines fluores, leur preparation et leurs applications en therapeutique
MA26626A1 (fr) Derives de 2"-desoxy-hygromycine a nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN86099A1 (fr) Nouveaux benzamides, leur procede de preparation et leur application dans le domaine therapeutique